<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="26748">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01922115</url>
  </required_header>
  <id_info>
    <org_study_id>13-1352</org_study_id>
    <nct_id>NCT01922115</nct_id>
  </id_info>
  <brief_title>The Effect of Anticholinergics on Cognitive Function in the Elderly</brief_title>
  <acronym>ACE</acronym>
  <official_title>The Effect of Anticholinergics on Cognitive Function in the Elderly: a Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of North Carolina, Chapel Hill</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>American Urogynecologic Society</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of North Carolina, Chapel Hill</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Anticholinergic medication is used to treat overactive bladder (OAB). A known side effect of
      this medication is cognitive dysfunction. OAB is more prevalent in the elderly population -
      a group that also has a higher baseline risk of cognitive dysfunction. Our objective is to
      evaluate the effect of an anticholinergic medication on cognitive function in elderly women.
      Subjects will be randomized to:1) trospium chloride or 2) placebo. There are three aims: 1)
      To evaluate changes in cognitive function in elderly women taking trospium versus placebo,
      using validated cognitive assessment tests. 2) To develop a useful battery of cognitive
      screening tests for monitoring the cognitive safety of OAB management. 3) To understand how
      the timing of cognitive changes relates to the timing of improvement in OAB symptoms. The
      investigators will recruit 60 women aged â‰¥ 65 with the diagnosis of OAB. Cognitive
      assessments will be performed at baseline and Week 1 and 4 after drug initiation using
      paper-based validated questionnaires. OAB improvement will be assessed with validated
      questionnaires.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Anticipated">January 2015</completion_date>
  <primary_completion_date type="Anticipated">January 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science</study_design>
  <primary_outcome>
    <measure>The Effect of Anticholinergics on Cognitive Functioning the Elderly</measure>
    <time_frame>24 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Cognitive function will be examined through tried tests and questionnaires.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Mental Competency</condition>
  <condition>Urinary Bladder, Overactive</condition>
  <condition>Cognitive Function</condition>
  <arm_group>
    <arm_group_label>TROSPIUM CHLORIDE</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Those with overactive bladder will be administered either a placebo or Sanctura XR extended release (Trospium chloride) for treatment (60 mg).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PLACEBO</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects may be administered a placebo rather than the Sanctura XR (Trospium Chloride).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trospium Chloride</intervention_name>
    <description>Subject will be administered either placebo or 60 mg dosage of Sanctura XR for treatment of overactive bladder.  Subject will take Sanctura XR once every morning. Blood will be drawn for plasma extraction at each visit.</description>
    <arm_group_label>TROSPIUM CHLORIDE</arm_group_label>
    <other_name>Sanctura XR</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>PLACEBO</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female 65 or older

          -  Diagnosis of OAB (ICS definition)

          -  English literacy

          -  Ability to swallow oral medication

          -  Cognitive ability to give consent

        Exclusion Criteria:

          -  Dementia/Depression/Delirium

          -  Current anticholinergic use (requires 2 week washout period)

          -  Current cholinesterase

          -  Urinary or gastric retention

          -  Severe decreased gastrointestinal motility

          -  Uncontrolled narrow-angle glaucoma

          -  Myasthenia gravis

          -  Diagnosis fo renal impairment (creatinine clearance &lt;30 mL/min)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elizabeth Geller, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UNC CHAPEL HILL</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>LAUREN E RUSTOWICZ, BS</last_name>
    <phone>919-843-8259</phone>
    <email>RUSTOWIC@EMAIL.UNC.EDU</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>ELIZABETH GELLER, MD</last_name>
    <phone>(919) 966-4717</phone>
    <email>EGELLER@MED.UNC.EDU</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Unc Chapel Hill Urogynecology A2 Clinic</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27517</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>ELIZABETH GELLER, MD</last_name>
      <phone>919-966-4717</phone>
      <email>EGELLER@MED.UNC.EDU</email>
    </contact>
    <investigator>
      <last_name>ELIZABETH GELLER, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 7, 2014</lastchanged_date>
  <firstreceived_date>August 9, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COGNITIVE FUNCTION</keyword>
  <keyword>OVERACTIVE BLADDER</keyword>
  <keyword>[C23.888.942.343.780]</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Urinary Bladder, Overactive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Trospium chloride</mesh_term>
    <mesh_term>Cholinergic Antagonists</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
